Absci Corporation
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Absci Corporation (Nasdaq: ABSI) is a biotechnology company that develops generative AI models and integrated platforms for de novo design of novel proteins, antibodies, and biologics to accelerate drug discovery and development. The company offers its Integrated Drug Creation Platform, which combines generative AI, wet-lab automation, and data sciences; key components include the ABS platform for AI-driven protein design, de novo antibody generation services, and optimization of existing biologics for properties such as developability, stability, and affinity; as well as proprietary datasets and cloud-based software tools for protein engineering. Absci serves pharmaceutical and biotechnology companies targeting oncology, immunology, and metabolic diseases, with operations primarily in the United States and partnerships extending to global markets. Founded in 2011 and headquartered in Vancouver, Washington, the company recently expanded its capabilities through a strategic collaboration with Astellas Pharma in 2024 to co-develop de novo antibodies for an undisclosed target using Absci's generative AI platform; in early 2025, Absci announced a $200 million funding round led by new institutional investors to scale its AI infrastructure and advance multiple programs into preclinical stages; additionally, it launched an upgraded version of its ABS platform featuring enhanced multimodal AI models for faster iteration in therapeutic design.
Absci to Participate in Upcoming Investor Conferences
Absci Corporation (ABSI) Q1 2026 Earnings Call Transcript
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates
Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026
Absci Corporation (ABSI) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference
MiMedx Group (NASDAQ:MDXG) & Absci (NASDAQ:ABSI) Head to Head Analysis
Absci Q4 Earnings Call Highlights
Absci: Downgrade To 'Hold' As ABS-101 On Back Burner And Pivot To ABS-201
Absci Corporation (ABSI) Q4 2025 Earnings Call Transcript
Absci Corporation (ABSI) Reports Q4 Loss, Misses Revenue Estimates
Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results
Absci Corporation (ABSI) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Absci Corporation (ABSI) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Absci Conference: Agentic AI Push and ABS-201 Hair-Loss Program Take Center Stage
Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer
Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026